Corbus Pharmaceuticals Completes Dosing Phase of 240-Patient Obesity Trial
The last participant in Corbus Pharmaceuticals' 240-patient CANYON-1 Phase 1b study of oral obesity candidate CRB-913 has completed the final clinical visit, with topline results expected in September 2026.